Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Could ATE see a similar headline?

<< Previous

Bullboard Posts

Next >>

Comment by nozzpackon Aug 23, 2021 6:16pm

314 Views

Post# 33752658

RE:Could ATE see a similar headline?

Just goes to show how innovative and unique medical solutions are in demand.

Almost certainly ATB 346 et al qualifies as innovative and unique.

And, shown to exceed the therapeutic benfits relative to disbenefits of its major competitors which have a near $trillion share of pain mitigation drugs.

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023